Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Key objectives in kidney cancer: treatment sequencing & refining clinical endpoints

Pavlos Msaouel • 3 Jun 2022
ASCO 2022
Genitourinary Cancer Kidney Cancer

Pavlos Msaouel, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, reflects on key takeaways in renal cell carcinoma at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, including the importance of treatment sequencing as well as refining clinical endpoints and methodologies. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Pavlos Msaouel

2:50
Sitravatinib and nivolumab in ccRCC following progression on antiangiogenic therapy
Pavlos Msaouel • 3 Jun 2022
1:11
Current standard of adjuvant therapy in kidney cancer
Pavlos Msaouel • 3 Jun 2022
2:35
Adjuvant therapy in RCC: harnessing prognostic information
Pavlos Msaouel • 3 Jun 2022
4:08
Bevacizumab plus erlotinib for RMC
Pavlos Msaouel • 4 Feb 2021

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals